US EditionJenscare released 30-day follow-up results of LuX-Valve Plus TRINITY study and 1-year follow-up results of JensClip TMVr at EuroPCR 2025
- Jenscare Scientific Co., Ltd. Presented the 30-day follow-up data from the TRINITY Trial evaluating LuX-Valve Plus, along with one-year results of the JensClip TMVr system, during the EuroPCR conference held in Paris, France, in 2025.
- The TRINITY trial involved 161 individuals with advanced tricuspid regurgitation considered at elevated risk for surgery, recruited from 20 international sites mainly located in Europe. In comparison, the JensClip study included 114 high-risk patients with degenerative mitral regurgitation across 18 centers in China.
- LuX-Valve Plus achieved a 97% device success rate with a mean operation time of 41.6 minutes and showed significant improvements in tricuspid regurgitation grade, NYHA classification, and quality of life at 30 days.
- The TRINITY trial reported a 14.8% composite event rate with 1.3% cardiovascular mortality, no myocardial infarctions or renal failures, and 95.7% of patients showing no above moderate tricuspid regurgitation at 30 days.
- The 1-year JensClip results demonstrated a 97% device success rate, 1.8% all-cause mortality, continuous improvement in mitral regurgitation and NYHA class, and increased patient quality of life, supporting Jenscare's position in innovative structural heart disease treatment.
59 Articles
59 Articles
Rutland Herald
Jenscare released 30-day follow-up results of LuX-Valve Plus TRINITY study and 1-year follow-up results of JensClip TMVr at EuroPCR 2025
BEIJING, June 2, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes…
Jenscare shares key valve study results at EuroPCR 2025
BEIJING, June 3, 2025 /PRNewswire/ -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 30-day follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes of JensClip, a proprietary TMVr system, at EuroPCR 2025 in Paris, France. 30-Day Follow-up Results of LuX-Valve Plus TRINITY Study TRINITY is a global prospecti…
Coverage Details
Bias Distribution
- 62% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
